Niki BioSolutions, Inc.
NIKI Healthcare Biotechnology
Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.
Follow NIKI
Niki BioSolutions, Inc. (NIKI) EV/Sales
As of 16 October 2026, Niki BioSolutions, Inc. (NIKI) trades at a EV/Sales of 1.3×. Over the past ten years it has ranged from −20.3× (June 2021) to 2.1× (June 2025); the current reading is higher than 87% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 0.5× | 11.39% |
| FY2022 | 0.5× | — |
| FY2021 | −3.4× | — |
| FY2020 | −20.3× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 39.5× | (38.85%) |
| Dec 2022 | 64.7× | (64.60%) |
| Jun 2022 | 183× | (14.86%) |
| Dec 2021 | 215× | (63.22%) |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. compare | −69.6× |
| SYBX Synlogic, Inc. compare | −0.2× |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| XCUR Exicure, Inc. compare | 0.2× |
| NIKI Niki BioSolutions, Inc. | 1.3× |
| SKYE Skye Bioscience, Inc. compare | 12.9× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 24.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)